AstraZeneca PLC (AZN): One of the Best Low Risk High Growth Firms

We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and AstraZeneca PLC (NYSE:AZN) ranks 5th on this list.

The growth story for AstraZeneca PLC (NYSE:AZN) is built on a massive, contractually visible expansion plan. Earlier this year, CEO Pascal Soriot reaffirmed the company’s goal to reach $80 billion in annual revenue by 2030. For a company currently reporting roughly $59 billion, this represents an industry-leading growth trajectory. In Q1 2026, cancer drug sales jumped 20%, fueled by blockbuster performance from Tagrisso, Imfinzi, and the accelerating Enhertu portfolio. These high-margin antibody-drug conjugates are viewed by hedge funds as the primary growth engine for the next decade. Safety in pharma comes from having so many products that a single failure cannot sink the stock. AstraZeneca owns 16 different blockbuster medicines, drugs generating over $1 billion annually.

Piper Sandler Maintains Overweight Rating on Blue Owl Capital (OWL)

In 2026 alone, AstraZeneca PLC (NYSE:AZN) is expecting results from more than 20 Phase III clinical trials. This strategy significantly de-risks the portfolio, as consistent positive readouts, like the recent Tozorakimab and Imfinzi successes in early April, provide a steady stream of new revenue. The firm is also uniquely positioned to handle geopolitical shifts better than many US-centric peers. Despite broader trade tensions, AstraZeneca is the largest multinational pharmaceutical company in China. In early 2026, it pledged an additional $15 billion in investments there, capturing high-volume demand in the world’s second-largest market.

READ NEXTIsrael Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.